TUMOUR VACCINES AND
CELLULAR THERAPY FOR BRAIN CANCER
Immunotherapy and cell-based approaches are being actively investigated in glioblastoma โ China is running some of the world's most active clinical programmes in this space.
analyticsAt a Glance
- check_circleDCVax-L dendritic cell vaccine showed 4.5-month median OS improvement vs placebo in the largest GBM immunotherapy trial
- check_circlePeptide vaccines (IMA950, SurVaxM) target GBM-specific antigens and are in Phase II trials
- check_circleChina has the world's most active CAR-T programme for solid tumours including GBM (EGFRvIII, IL13Rฮฑ2, GD2 targets)
- check_circleCancerFax connects GBM patients with ongoing Chinese cellular therapy trials not available elsewhere
Why Immunotherapy Is Challenging in Brain Cancer
The brain's immune-privileged environment, GBM's highly immunosuppressive tumour microenvironment, and the blood-brain barrier make glioblastoma one of the hardest cancers for immunotherapy. Despite this, multiple approaches are showing signal.
โGBM is the last frontier for immunotherapy โ but the progress made in the last five years is the most in the history of this disease.โ
Immunosuppressive Microenvironment
GBM actively recruits regulatory T-cells and myeloid-derived suppressor cells, turning off immune responses near the tumour. Overcoming this is the central challenge for all immunotherapy approaches.
Active Clinical Programmes
Despite challenges, dendritic cell vaccines (DCVax-L), peptide vaccines (IMA950, SurVaxM), oncolytic viruses, and CAR-T are all in active trials โ China leads in solid-tumour CAR-T programmes.
Tumour Vaccine Approaches in GBM: What the Evidence Shows
Multiple vaccine strategies are being investigated in glioblastoma โ each targeting different tumour antigens or immune activation pathways.
| Vaccine Approach | Mechanism | Key Trial / Evidence | Status |
|---|---|---|---|
| DCVax-L (dendritic cell) | Patient-derived dendritic cells loaded with tumour lysate โ activates T-cell response | NWBO Phase III: +4.5 months mOS in newly diagnosed GBM | Phase III complete โ expanded access in USA/UK |
| IMA950 (peptide vaccine) | Targets 11 GBM-associated peptides โ activates cytotoxic T-cells | Phase II โ best results in MGMT-methylated tumours | Phase II ongoing |
| SurVaxM (survivin peptide) | Targets survivin โ anti-apoptotic protein overexpressed in GBM | Phase II โ mOS 25 months vs 15 months historical control | Phase II โ US trials |
| EGFRvIII vaccine (rindopepimut) | Targets EGFRvIII mutation โ present in 25-30% of GBMs | ACT IV trial: no benefit vs placebo at interim analysis | Development discontinued โ antigen escape observed |
| Oncolytic virus (G47ฮ) | Live attenuated herpes virus โ directly kills GBM cells and stimulates immunity | Japanese conditional approval 2021 โ response in recurrent GBM | Approved in Japan โ trials in China ongoing |
CAR-T Cell Therapy for Brain Tumours: China's Leading Role
CAR-T in solid tumours is far harder than blood cancers โ but China's oncology centres have the world's most active early-phase programmes targeting GBM-specific antigens.
EGFRvIII CAR-T
Targets the EGFRvIII deletion mutation present in ~25% of GBMs. Early phase Chinese trials have shown localised delivery (intratumoral/intracerebroventricular) produces better results than IV infusion. Case reports of durable responses.
IL13Rฮฑ2 and GD2 CAR-T
IL13Rฮฑ2 is overexpressed in ~75% of GBMs. GD2 is expressed in H3K27M-mutant diffuse midline gliomas. City of Hope (USA) and multiple Chinese centres are running Phase I trials showing early signals.
Key Numbers from GBM Immunotherapy Trials
Selected efficacy data from the most advanced immunotherapy trials in glioblastoma.
- +4.5 moMedian OS benefit โ DCVax-L vs placeboNWBO Phase III trial, newly diagnosed and recurrent GBM patients combined.
- 25 moMedian OS โ SurVaxM Phase IIvs 15 months historical control in newly diagnosed unmethylated GBM.
- 75%GBMs expressing IL13Rฮฑ2Making IL13Rฮฑ2 one of the most prevalently expressed GBM CAR-T targets.
China vs Western Centres for GBM Cellular Therapy Access
Chinese oncology centres offer access to cellular therapy programmes not available in Western countries โ but with different infrastructure and language considerations.
China Advantages
- Most active solid-tumour CAR-T programme globallyChina has more active CAR-T trials for solid tumours (including GBM) than any other country.
- Oncolytic virus trials activeG47ฮ and other oncolytic virus programmes are enrolling in China with easier international patient access than Japan.
- Combined approaches availableChinese centres combine cellular therapy with temozolomide, bevacizumab, and TTFields in integrated protocols.
Considerations
- Language barrierClinical teams communicate in Mandarin โ interpreter support from CancerFax is essential for international patients.
- Trial eligibility criteria are strictCAR-T trials require KPS โฅ70, adequate organ function, no systemic steroids โ many recurrent GBM patients do not qualify.
- Evidence is early-phaseMost Chinese GBM cellular therapy programmes are Phase IโII. DCVax-L is the only Phase III-positive cellular approach.
Frequently Asked Questions
Cellular Therapy for GBM
Is CAR-T approved for glioblastoma anywhere?
No CAR-T product is currently approved for GBM anywhere in the world. All GBM CAR-T programmes are in clinical trials โ Phase I and Phase II. The most accessible active trials for international patients are in China, where CancerFax can facilitate evaluation and trial access.
Can I access DCVax-L?
DCVax-L (Northwest Biotherapeutics) is available through expanded access in the USA and UK for patients who meet criteria after the Phase III trial completed. The manufacturing requires fresh tumour tissue collected at surgery โ patients who did not bank tissue at initial surgery are typically not eligible. CancerFax can advise on eligibility.
What is CIK therapy and is it available for GBM?
CIK (cytokine-induced killer) cells are a less engineered cellular therapy available at Chinese hospitals. Evidence for CIK in GBM is limited โ it is primarily used in blood and liver cancers. For GBM, CAR-T and dendritic cell vaccines have stronger rationale. CancerFax would not typically recommend CIK as the primary approach for GBM.
Does CancerFax have access to Chinese GBM CAR-T trials?
CancerFax works with several Chinese centres running GBM cellular therapy programmes including Xuanwu Hospital Beijing and PUTH. Trial access depends on current enrolment status, eligibility, and the patient's clinical profile. CancerFax reviews each case individually before advising on access.
More from the Brain Cancer and TTFields Resource Library
Explore related guides on glioblastoma treatment, clinical trials, and advanced options in China.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Explore Cellular Therapy Options for Brain Cancer
CancerFax reviews your GBM or brain tumour case and identifies which cellular or vaccine-based programmes โ clinical trials or compassionate access โ you may be eligible for in China or India.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.